Clinical trials
for patients

The purpose of this clinical trial is to investigate the drug’s safety, how well you tolerate the drug, and its antitumor activity, and to determine the optimal dose when administered daily as an oral tablet.

The main goal of this clinical research trial is to determine whether the investigational drug, RPTR-1-201, is safe and what side effects it may cause. In some parts of the trial, RPTR-1-201 will be given alone, and in other parts, it will be given together with another cancer drug called pembrolizumab. The goal is to assess the safety of RPTR-1-201 when used alone and when used together with pembrolizumab.

The aim of this study is to compare the effects of the study drug, pumitamig (also known as BNT327 or PM8002), with those of a placebo, when both are administered in combination with chemotherapy.

The primary objective is to evaluate raludotatug deruxtecan, also known as R-DXd, at each dose level.

The primary objectives of this study are to investigate whether taking metformin slows the loss of lung function and halts the progression of emphysema (lung damage). We also want to explore whether some of the conditions associated with aging and very common in patients with this disease—such as cancers (especially lung cancer), angina, heart attacks, or kidney damage—can be prevented by taking metformin.

The primary objective of this clinical trial is to determine the safety and efficacy of the study drug 12GRWD5769, either alone or in combination with another drug called Libtayo® (cemiplimab), in the treatment of advanced or metastatic solid tumors.

The aim of this study is to investigate the safety and efficacy of the Dara-VRD regimen followed by Ciltacabtagene autoleucel (cilta-cel), a CAR-T therapy, in patients diagnosed with high-risk MMq.

The purpose of this study is to determine whether CPV-104 (the drug being studied) is safe for use in people (safety), the manageability of side effects (tolerability), the blood concentrations of CPV-104 and factor H (an important protein in the human body involved in the immune system) in the blood (pharmacokinetics), and whether CPV-104 triggers a defensive reaction in the body against foreign substances (immunogenicity).

The purpose of this trial is: to investigate a potential new combination of trial drugs (consisting of the trial drug, which is an antibody-drug conjugate [ADC] called BNT326, in combination with an immunotherapy drug, BNT327) to determine the recommended dose of the trial drug; to evaluate the safety of the combination of study drugs; and to obtain information on its efficacy for advanced or metastatic NSCLC.

The aim is to determine whether the drug BI-1206, which has not yet been approved for marketing, will be effective in treating advanced solid tumors and how safe it is for people. In this study, BI-1206 will be administered in combination with pembrolizumab, an approved drug marketed as Keytruda